These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 31262348)

  • 41. [Clinical efficacy of noliprel in the treatment of hypertension. Main results of ETALON].
    Oganov RG; Nebieridze DV
    Kardiologiia; 2004; 44(3):66-9. PubMed ID: 15489830
    [No Abstract]   [Full Text] [Related]  

  • 42. Evaluation of the efficacy and tolerability of combination therapy with candesartan cilexetil and amlodipine besilate compared with candesartan cilexetil monotherapy and amlodipine besilate monotherapy in Japanese patients with mild-to-moderate essential hypertension: a multicenter, 12-week, randomized, double-blind, placebo-controlled, parallel-group study.
    Rakugi H; Ogihara T; Miyata Y; Sasai K; Totsuka N
    Clin Ther; 2012 Apr; 34(4):838-48. PubMed ID: 22440192
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Efficacy, tolerability, and quality of life of losartan, alone or with hydrochlorothiazide, versus nifedipine GITS in patients with essential hypertension.
    Weir MR; Elkins M; Liss C; Vrecenak AJ; Barr E; Edelman JM
    Clin Ther; 1996; 18(3):411-28. PubMed ID: 8829017
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Short-term antihypertensive efficacy of perindopril according to clinical profile of 3,188 patients: A meta-analysis.
    Gasowski J; Wilkins A; Drzewoski J; Kłoś J; Gaciong Z; Kabat M; Grodzicki T
    Cardiol J; 2010; 17(3):259-66. PubMed ID: 20535716
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Combination of an ACE inhibitor and indapamide improves blood pressure control, but attenuates the beneficial effects of ACE inhibition on plasma adiponectin in patients with essential hypertension.
    Huang SS; Wu TC; Lin SJ; Chen JW
    Circ J; 2009 Dec; 73(12):2282-7. PubMed ID: 19789415
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Efficacy and tolerability of candesartan cilexetil/hydrochlorothiazide and amlodipine in patients with poorly controlled mild-to-moderate essential hypertension.
    Fogari R; Mugellini A; Derosa G;
    J Renin Angiotensin Aldosterone Syst; 2007 Sep; 8(3):139-44. PubMed ID: 17907102
    [TBL] [Abstract][Full Text] [Related]  

  • 47. 24-Hour blood pressure response to lower dose (30 mg) fimasartan in Korean patients with mild to moderate essential hypertension.
    Lee HY; Kim CH; Song JK; Chae SC; Jeong MH; Kim DS; Oh BH
    Korean J Intern Med; 2017 Nov; 32(6):1025-1036. PubMed ID: 29032666
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Treatment of hypertension in patients 80 years of age or older.
    Beckett NS; Peters R; Fletcher AE; Staessen JA; Liu L; Dumitrascu D; Stoyanovsky V; Antikainen RL; Nikitin Y; Anderson C; Belhani A; Forette F; Rajkumar C; Thijs L; Banya W; Bulpitt CJ;
    N Engl J Med; 2008 May; 358(18):1887-98. PubMed ID: 18378519
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Cardioprotective effect of fimasartan, a new angiotensin receptor blocker, in a porcine model of acute myocardial infarction.
    Sim DS; Jeong MH; Song HC; Kim J; Chong A; Bom HS; Jeong IS; Oh SG; Kim JM; Park DS; Kim JH; Lim KS; Kim MS; Ryu SH; Kim HK; Kim SS; Jang SY; Cho JY; Jeong HC; Lee KH; Park KH; Yoon NS; Yoon HJ; Kim KH; Hong YJ; Park HW; Kim JH; Ahn Y; Cho JG; Park JC; Kang JC
    J Korean Med Sci; 2015 Jan; 30(1):34-43. PubMed ID: 25552881
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Twenty-four-hour ambulatory blood pressure monitoring efficacy of perindopril/indapamide first-line combination in hypertensive patients: the REASON study.
    Mallion JM; Chamontin B; Asmar R; De Leeuw PW; O'Brien E; Duprez D; O'Rourke MF; Rahn KH; Romero R; Battegay E; Hitzenberger G; Safar ME;
    Am J Hypertens; 2004 Mar; 17(3):245-51. PubMed ID: 15001199
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Perindopril/indapamide combination in the first-line treatment of hypertension and end-organ protection.
    Gosse P
    Expert Rev Cardiovasc Ther; 2006 May; 4(3):319-33. PubMed ID: 16716093
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A randomized, double blind, placebo-controlled, multicenter phase II trial of Allisartan Isoproxil in essential hypertensive population at low-medium risk.
    Li Y; Li XH; Huang ZJ; Yang GP; Zhang GG; Zhao SP; Guo Y; Lu SJ; Ma JL; Meng FB; Chen P; Yuan H
    PLoS One; 2015; 10(2):e0117560. PubMed ID: 25693004
    [TBL] [Abstract][Full Text] [Related]  

  • 53. You should treat patients over the age of 80 who have hypertension.
    Lundberg GD
    Medscape J Med; 2008; 10(8):185. PubMed ID: 18924637
    [No Abstract]   [Full Text] [Related]  

  • 54. Efficacy and safety of an oral fixed low-dose perindopril 2 MG/indapamide 0.625 MG combination: a randomized, double-blind, placebo-controlled study in elderly patients with mild to moderate hypertension.
    Castaigne A; Chalmers J; Morgan T; Chastang C; Feldmann L; Guez D
    Clin Exp Hypertens; 1999 Oct; 21(7):1097-110. PubMed ID: 10513830
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Use of antihypertension agents for the suppression of arterial pulse pressure waveforms in patients with intracranial aneurysms.
    Turner CL; Wilkinson IB; Kirkpatrick PJ
    J Neurosurg; 2006 Apr; 104(4):531-6. PubMed ID: 16619656
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Rationale, design and patient baseline characteristics of OlmeSartan and calcium antagonists randomized (OSCAR) study: a study comparing the incidence of cardiovascular events between high-dose angiotensin II receptor blocker (ARB) monotherapy and combination therapy of ARB with calcium channel blocker in Japanese elderly high-risk hypertensive patients (ClinicalTrials. gov no. NCT00134160).
    Ogawa H; Kim-Mitsuyama S; Jinnouchi T; Matsui K; Arakawa K
    Hypertens Res; 2009 Jul; 32(7):575-80. PubMed ID: 19444280
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Microalbuminuria in patients with hypertension and cardiovascular comorbidity, REAL observational study of treatment with Irbesartan/HCTZ].
    Tschöpe C; Tschöpe R; Unger T
    MMW Fortschr Med; 2006 Jun; 148(25):48. PubMed ID: 16859162
    [No Abstract]   [Full Text] [Related]  

  • 58. I-ADD study: assessment of efficacy and safety profile of irbesartan/amlodipine fixed-dose combination therapy compared with irbesartan monotherapy in hypertensive patients uncontrolled with irbesartan 150 mg monotherapy: a multicenter, phase III, prospective, randomized, open-label with blinded-end point evaluation study.
    Bobrie G;
    Clin Ther; 2012 Aug; 34(8):1720-34.e3. PubMed ID: 22853847
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Treatment of hypertension in patients older than 80 years].
    Rump LC; Nitschmann S
    Internist (Berl); 2009 Sep; 50(9):1169-70. PubMed ID: 19690822
    [No Abstract]   [Full Text] [Related]  

  • 60. Antihypertensive combination therapy: optimizing blood pressure control and cardiovascular risk reduction.
    Nesbitt SD
    J Clin Hypertens (Greenwich); 2007 Nov; 9(11 Suppl 4):26-32. PubMed ID: 17978604
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.